Search
Use the filters to narrow by type of content
Looking for a Publication? Search the bibliography for: publications use oral corticosteroids risk acute myocardial infarction
… vaccination – adolescents and young adults are at risk for under-immunization, especially those with health …
… individuals with Alzheimer’s and their caregivers and to use that information to develop treatments that can help … well as their current and former caregivers and those at risk for developing any of these conditions. With the …
… to access and quality of research. With the rise in use of mobile computing devices, the field may again see …
… as mixing and matching vaccines, boosters, and vaccine use in children are fundamentally changing that landscape. …
… numerous unapproved product dossiers (UPDs) and unapproved use dossiers (UUDs) in various therapeutic areas, including … for creating an unapproved product dossier or unapproved use dossier While this may seem straightforward, … the inclusion of clinical data affect planned or pending publications? Manufacturers should determine the appropriate …
… The generally preferred method of measuring QALYs is to use quality-of-life or utility data. Australian-based preference weights are preferred for use in the scoring algorithm to calculate the utility … utility weights could also be used, along with the use of utility weights published in the literature. …
… (FDA) recently released draft guidance that introduces the use of Diversity Action Plans (DAPs). These plans outline … the intended patient population for the medical product’s use. Additionally, DAPs should include background information on disease understanding, associated risk factors, and demographic prevalence and incidence of the …
… To ensure equitable decision-making, manufacturers should use a range of evidence sources and techniques, including …
… of GI illnesses. Recent projects have included: Benefit-risk preference studies Cohort and case-control studies … research Reimbursement and value communication strategies Risk management programs including development, …
Tailoring Cost-Effectiveness Modeling Methodologies for Multiple Sclerosis Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in patients with inadequate response to disease-modifying therapies in relapsing-remitting multiple …